心力衰竭的药理管理:以患者为中心的方法
Guglielmo Fibbi1,2,3, Ryosuke Sato1,2, Mirela Vatic1,2
1Department of Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany.
Expert opinion on pharmacotherapy
|October 22, 2024
概括
心力衰竭 (HF) 药物治疗正在推进,但患者的结果仍然令人担忧. 考虑并发症和日常生活活动的个性化方法对于改善心力衰竭管理至关重要.
科学领域:
- 心脏病学 心脏病学
- 药物治疗 药物治疗
- 临床研究 临床研究
背景情况:
- 心力衰竭 (HF) 是一个重要的全球健康问题,患病率和死亡率很高.
- 尽管治疗方面取得了进展,但由于其复杂性和并发症,HF管理仍然具有挑战性.
研究的目的:
- 审查心力衰竭目前的药物治疗方法.
- 探索HF药物治疗的未来方向.
主要方法:
- 对HF最近的大型结局试验的审查.
- 分析当前的国际HF治疗指南.
- 关于以患者为中心的药物治疗的专家意见.
主要成果:
- 最近的药物治疗和干预措施已经降低了HF死亡率和发病率,但病率仍然很高.
- 以患者为中心的方法,考虑到并发症,对于优化HF药物治疗至关重要.
- 专注于预防住院和改善日常生活活动变得越来越重要.
结论:
- 持续的研究和指南更新是有效的高频管理所必需的.
- 个性化药物治疗和专注于以患者为中心的结果是推动HF护理的关键.
相关概念视频
Heart Failure V: Medical Management
1
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
394
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
394
Heart Failure V: Nursing Interventions
1
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
1
Cardiomyopathy V: Interprofessional Care
1
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
1
Heart Failure VI: Adjunct Therapies
1
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
1
Heart Failure Drugs: β-Blockers
320
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320


